-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Some -X- _ O
isoquinoline -X- _ B-Intervention
alkaloids -X- _ I-Intervention
from -X- _ I-Intervention
Macleaya -X- _ I-Intervention
cordata -X- _ I-Intervention
( -X- _ I-Intervention
Willd -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ I-Intervention
R. -X- _ I-Intervention
Br. -X- _ I-Intervention
( -X- _ I-Intervention
Bo -X- _ I-Intervention
Luo -X- _ I-Intervention
Hui -X- _ I-Intervention
) -X- _ I-Intervention
exhibited -X- _ O
antibacterial -X- _ O
, -X- _ O
antiparasitic -X- _ O
, -X- _ O
antitumor -X- _ O
, -X- _ O
and -X- _ O
analgesic -X- _ O
effects. -X- _ O
The -X- _ O
targets -X- _ O
of -X- _ O
these -X- _ O
isoquinoline -X- _ O
alkaloids -X- _ O
are -X- _ O
undefined. -X- _ O
This -X- _ O
study -X- _ O
aims -X- _ O
to -X- _ O
investigate -X- _ O
the -X- _ O
compound–target -X- _ O
interaction -X- _ O
network -X- _ O
and -X- _ O
potential -X- _ O
pharmacological -X- _ O
actions -X- _ O
of -X- _ O
isoquinoline -X- _ B-Intervention
alkaloids -X- _ I-Intervention
of -X- _ I-Intervention
M. -X- _ I-Intervention
cordata -X- _ I-Intervention
by -X- _ O
reverse -X- _ O
pharmacophore -X- _ O
database -X- _ O
screening. -X- _ O
METHODS -X- _ O
: -X- _ O
The -X- _ O
targets -X- _ O
of -X- _ O
26 -X- _ B-Intervention
isoquinoline -X- _ I-Intervention
alkaloids -X- _ I-Intervention
identified -X- _ I-Intervention
from -X- _ I-Intervention
M. -X- _ I-Intervention
cordata -X- _ I-Intervention
were -X- _ O
predicted -X- _ O
by -X- _ O
a -X- _ O
pharmacophore-based -X- _ O
target -X- _ O
fishing -X- _ O
approach. -X- _ O
Discovery -X- _ O
Studio -X- _ O
3.5 -X- _ O
and -X- _ O
two -X- _ O
pharmacophore -X- _ O
databases -X- _ O
( -X- _ O
PharmaDB -X- _ O
and -X- _ O
HypoDB -X- _ O
) -X- _ O
were -X- _ O
employed -X- _ O
for -X- _ O
the -X- _ O
target -X- _ O
profiling. -X- _ O
A -X- _ O
compound–target -X- _ O
interaction -X- _ O
network -X- _ O
of -X- _ O
M. -X- _ O
cordata -X- _ O
was -X- _ O
constructed -X- _ O
and -X- _ O
analyzed -X- _ O
by -X- _ O
Cytoscape -X- _ O
3.0. -X- _ O
RESULTS -X- _ O
: -X- _ O
Thirteen -X- _ B-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
65 -X- _ I-Outcome
predicted -X- _ I-Outcome
targets -X- _ I-Outcome
identified -X- _ I-Outcome
by -X- _ I-Outcome
PharmaDB -X- _ I-Outcome
were -X- _ I-Outcome
confirmed -X- _ I-Outcome
as -X- _ I-Outcome
targets -X- _ I-Outcome
by -X- _ I-Outcome
HypoDB -X- _ I-Outcome
screening. -X- _ I-Outcome
The -X- _ O
targets -X- _ O
in -X- _ O
the -X- _ O
interaction -X- _ O
network -X- _ O
of -X- _ O
M. -X- _ B-Outcome
cordata -X- _ I-Outcome
were -X- _ I-Outcome
involved -X- _ I-Outcome
in -X- _ I-Outcome
cancer -X- _ I-Outcome
( -X- _ I-Outcome
31 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
microorganisms -X- _ I-Outcome
( -X- _ I-Outcome
12 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
neurodegeneration -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
inflammation -X- _ I-Outcome
and -X- _ I-Outcome
autoimmunity -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
parasitosis -X- _ I-Outcome
( -X- _ I-Outcome
5 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
injury -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
pain -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
targets -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Dihydrochelerythrine -X- _ I-Outcome
( -X- _ I-Outcome
C6 -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
hit -X- _ I-Outcome
23 -X- _ I-Outcome
fitting -X- _ I-Outcome
targets. -X- _ I-Outcome
Macrophage -X- _ I-Outcome
migration -X- _ I-Outcome
inhibitory -X- _ I-Outcome
factor -X- _ I-Outcome
( -X- _ I-Outcome
MIF -X- _ I-Outcome
) -X- _ I-Outcome
hits -X- _ I-Outcome
15 -X- _ I-Outcome
alkaloids -X- _ I-Outcome
( -X- _ I-Outcome
C1–2 -X- _ I-Outcome
, -X- _ I-Outcome
C11–16 -X- _ I-Outcome
, -X- _ I-Outcome
C19–25 -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
promising -X- _ I-Outcome
target -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
cancer. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Through -X- _ B-Outcome
in -X- _ I-Outcome
silico -X- _ I-Outcome
target -X- _ I-Outcome
fishing -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
anticancer -X- _ I-Outcome
, -X- _ I-Outcome
anti-inflammatory -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
analgesic -X- _ I-Outcome
effects -X- _ I-Outcome
of -X- _ I-Outcome
M. -X- _ I-Outcome
cordata -X- _ I-Outcome
were -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
significant -X- _ I-Outcome
among -X- _ I-Outcome
many -X- _ I-Outcome
possible -X- _ I-Outcome
activities. -X- _ I-Outcome
The -X- _ I-Outcome
possible -X- _ I-Outcome
anticancer -X- _ I-Outcome
effects -X- _ I-Outcome
were -X- _ I-Outcome
mainly -X- _ I-Outcome
contributed -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
isoquinoline -X- _ I-Outcome
alkaloids -X- _ I-Outcome
as -X- _ I-Outcome
active -X- _ I-Outcome
components -X- _ I-Outcome
. -X- _ O

